PriceTargets.com logo

NASDAQ:TNDM - Tandem Diabetes Care Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $106.10
  • Forecasted Upside: 76.54 %
  • Number of Analysts: 7
  • Breakdown:
  • 1 Sell Ratings
  • 2 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$60.10 As of 08/8/2022 01:00 AM ET
▲ +0.56 (0.94%)

This chart shows the closing price for TNDM by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Tandem Diabetes Care Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for TNDM and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for TNDM

Analyst Price Target is $106.10
▲ +76.54% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Tandem Diabetes Care in the last 3 months. The average price target is $106.10, with a high forecast of $150.00 and a low forecast of $49.00. The average price target represents a 76.54% upside from the last price of $60.10.

This chart shows the closing price for TNDM for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 7 investment analysts is to hold stock in Tandem Diabetes Care. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 10 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
2/14/2021
  • 0 strong buy ratings
  • 10 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
5/15/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
8/13/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
11/11/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
2/9/2022
  • 0 strong buy ratings
  • 7 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
5/10/2022
  • 0 strong buy ratings
  • 7 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
7/9/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
8/8/2022

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/9/2022Wells Fargo & CompanyDowngradeOverweight ➝ Underweight$82.00 ➝ $49.00Low
8/4/2022Lake Street CapitalLower Price Target$200.00 ➝ $150.00Low
8/4/2022CowenLower Price Target$141.00 ➝ $107.00Low
8/4/2022Piper SandlerLower Price TargetOverweight$120.00 ➝ $80.00N/A
8/4/2022Wells Fargo & CompanyLower Price TargetOverweight$166.00 ➝ $82.00Low
8/4/2022Raymond JamesLower Price TargetOutperform$125.00 ➝ $90.00Low
8/4/2022CowenLower Price Target$141.00 ➝ $107.00Low
8/4/2022CitigroupLower Price Target$107.00 ➝ $98.00Low
5/17/2022CitigroupLower Price Target$155.00 ➝ $130.00Medium
5/5/2022OppenheimerLower Price Target$142.00 ➝ $130.00High
5/5/2022Piper SandlerLower Price Target$170.00 ➝ $120.00High
4/18/2022SVB LeerinkReiterated RatingMarket PerformHigh
3/2/2022Bank of AmericaInitiated CoverageNeutral ➝ Neutral$130.00Low
2/23/2022Wells Fargo & CompanyBoost Price TargetOverweight$160.00 ➝ $166.00High
2/23/2022CitigroupLower Price TargetBuy$163.00 ➝ $155.00High
2/23/2022SVB LeerinkLower Price TargetMarket Perform$140.00 ➝ $120.00High
1/19/2022Wells Fargo & CompanyUpgradeEqual Weight ➝ Overweight$137.00 ➝ $160.00High
12/7/2021Lake Street CapitalBoost Price TargetBuy$165.00 ➝ $200.00High
12/6/2021Piper SandlerBoost Price TargetOverweight$140.00 ➝ $150.00High
11/4/2021Wells Fargo & CompanyBoost Price TargetEqual Weight$121.00 ➝ $137.00High
11/4/2021SVB LeerinkBoost Price TargetMarket Perform$135.00 ➝ $140.00High
11/4/2021Raymond JamesBoost Price TargetOutperform$120.00 ➝ $138.00High
11/4/2021Piper SandlerBoost Price TargetOverweight$132.00 ➝ $140.00High
9/24/2021SVB LeerinkBoost Price TargetMarket Perform$123.00 ➝ $135.00Low
8/5/2021SVB LeerinkBoost Price TargetMarket Perform ➝ Market Perform$102.00 ➝ $123.00Low
8/5/2021OppenheimerBoost Price TargetOutperform$135.00 ➝ $140.00Low
8/5/2021Craig HallumBoost Price TargetBuy$140.00 ➝ $153.00High
8/5/2021Wells Fargo & CompanyBoost Price TargetEqual Weight$112.00 ➝ $121.00High
8/5/2021Raymond JamesBoost Price TargetOutperform$115.00 ➝ $120.00Medium
5/24/2021BarclaysInitiated CoverageUnderweight$90.00Low
5/6/2021OppenheimerBoost Price Target$130.00 ➝ $135.00Low
5/6/2021SVB LeerinkBoost Price TargetMarket Perform$95.00 ➝ $102.00High
4/1/2021SVB LeerinkLower Price TargetMarket Perform$115.00 ➝ $95.00Low
3/31/2021OppenheimerReiterated RatingBuyHigh
2/25/2021Lake Street CapitalBoost Price TargetBuy$137.00 ➝ $150.00High
12/15/2020Wells Fargo & CompanyDowngradeOverweight ➝ Equal Weight$105.00High
11/6/2020Raymond JamesBoost Price TargetOutperform$116.00 ➝ $124.00High
11/6/2020SVB LeerinkBoost Price TargetMarket Perform$120.00 ➝ $130.00High
11/6/2020Piper SandlerBoost Price TargetOverweight$125.00 ➝ $132.00High
9/21/2020OppenheimerReiterated RatingBuy$120.00High
8/28/2020SVB LeerinkBoost Price TargetMarket Perform$115.00 ➝ $120.00Low
8/20/2020Wells Fargo & CompanyInitiated CoverageOverweight$120.00High
7/31/2020Raymond JamesBoost Price TargetOutperform$95.00 ➝ $116.00Low
7/31/2020Craig HallumBoost Price TargetBuy$102.00 ➝ $140.00High
7/31/2020Lake Street CapitalBoost Price TargetPositive ➝ Buy$125.00 ➝ $137.00High
7/31/2020SVB LeerinkBoost Price TargetMarket Perform$105.00 ➝ $115.00High
7/31/2020GuggenheimUpgradeNeutral ➝ Buy$130.00High
7/31/2020Piper SandlerBoost Price TargetOverweight$90.00 ➝ $125.00High
7/7/2020CowenBoost Price TargetPositive ➝ Outperform$85.00 ➝ $110.00Low
7/6/2020CitigroupUpgradeNeutral ➝ Buy$94.00 ➝ $120.00Low
6/30/2020OppenheimerInitiated CoverageBuy$102.00Low
6/30/2020Piper SandlerReiterated RatingBuy$90.00Low
6/30/2020Bank of AmericaReiterated RatingHold$100.00Low
6/30/2020CowenReiterated RatingBuy$85.00Low
6/22/2020UBS GroupBoost Price TargetBuy$98.00 ➝ $106.00Low
6/22/2020OppenheimerBoost Price TargetReduce ➝ Outperform$92.00 ➝ $102.00Low
6/18/2020Lake Street CapitalBoost Price Target$100.00 ➝ $125.00Low
6/18/2020Raymond JamesBoost Price TargetOutperform$88.00 ➝ $95.00Low
6/17/2020OppenheimerInitiated CoverageBuy$92.00Low
6/3/2020CitigroupBoost Price TargetAverage ➝ Neutral$81.00 ➝ $94.00Low
5/22/2020Bank of AmericaBoost Price TargetNeutral$85.00 ➝ $95.00Low
5/1/2020UBS GroupLower Price TargetBuy$100.00 ➝ $98.00High
5/1/2020CitigroupBoost Price TargetNeutral$74.00 ➝ $81.00High
5/1/2020Stifel NicolausBoost Price TargetHold$65.00 ➝ $75.00Medium
5/1/2020OppenheimerReiterated RatingBuy$92.00High
5/1/2020SVB LeerinkBoost Price TargetMarket Perform$85.00 ➝ $88.00High
4/27/2020Raymond JamesLower Price TargetOutperform$91.00 ➝ $81.00Low
4/24/2020SVB LeerinkDowngradeOutperform ➝ Market PerformLow
4/20/2020Craig HallumLower Price TargetBuy$108.00 ➝ $102.00Medium
3/27/2020CitigroupLower Price TargetNeutral$89.00 ➝ $74.00High
3/23/2020GuggenheimDowngradeBuy ➝ NeutralHigh
3/4/2020CitigroupInitiated CoverageNeutral$89.00Medium
2/25/2020OppenheimerBoost Price Target$84.00 ➝ $97.00High
2/25/2020Piper SandlerBoost Price TargetOverweight$70.00 ➝ $90.00High
2/25/2020Craig HallumBoost Price TargetBuy$92.00 ➝ $108.00High
2/25/2020Stifel NicolausBoost Price TargetHold$70.00 ➝ $77.00High
2/25/2020Raymond JamesBoost Price TargetOutperform$85.00 ➝ $91.00High
2/25/2020CowenReiterated RatingOutperform$85.00 ➝ $90.00High
2/13/2020CowenBoost Price TargetOutperform$70.00 ➝ $85.00Medium
2/12/2020Craig HallumReiterated RatingBuy$92.00High
2/5/2020Raymond JamesInitiated CoverageOutperform$85.00Low
2/4/2020Robert W. BairdDowngradeOutperform ➝ Neutral$71.00 ➝ $75.00Low
12/13/2019Craig HallumReiterated RatingBuy$92.00Low
10/17/2019GuggenheimInitiated CoverageBuy$76.00Low
10/4/2019UBS GroupUpgradeNeutral ➝ Buy$75.00Low
8/2/2019OppenheimerBoost Price Target$80.00 ➝ $84.00Medium
6/17/2019Lake Street CapitalReiterated RatingBuyMedium
5/17/2019Bank of AmericaReiterated RatingNeutral$65.00Medium
5/13/2019SVB LeerinkInitiated CoverageOutperform ➝ Outperform$83.00Low
5/1/2019OppenheimerBoost Price TargetOutperform$68.00 ➝ $80.00Medium
5/1/2019Stifel NicolausBoost Price TargetHold ➝ Hold$58.00 ➝ $70.00Medium
5/1/2019Craig HallumReiterated RatingBuy$70.00 ➝ $84.00High
4/30/2019UBS GroupBoost Price TargetNeutral ➝ Neutral$53.00 ➝ $66.00High
3/8/2019BMO Capital MarketsInitiated CoverageOutperform ➝ Outperform$77.00High
3/5/2019Bank of AmericaBoost Price TargetNeutral$59.00 ➝ $65.00Low
2/27/2019OppenheimerBoost Price TargetOutperform$57.00 ➝ $68.00Medium
2/27/2019CowenBoost Price TargetOutperform$40.00 ➝ $60.00Medium
2/27/2019Craig HallumBoost Price TargetBuy$59.00 ➝ $70.00Medium
2/27/2019Lake Street CapitalBoost Price TargetBuy ➝ Buy$60.00 ➝ $100.00High
2/27/2019Piper Jaffray CompaniesUpgradeOverweight$67.00High
2/15/2019Robert W. BairdBoost Price TargetOutperform$46.00 ➝ $55.00Medium
11/27/2018UBS GroupInitiated CoverageNeutral$36.00High
11/21/2018Robert W. BairdUpgradeNeutral ➝ Outperform$46.00High
11/9/2018OppenheimerSet Price TargetBuy$57.00Medium
11/3/2018Lake Street CapitalSet Price TargetBuy$60.00High
11/2/2018Craig HallumSet Price TargetBuy$59.00High
11/2/2018OppenheimerSet Price TargetBuy$57.00High
10/15/2018Lake Street CapitalSet Price TargetBuy$60.00High
9/26/2018Dougherty & CoBoost Price TargetBuy$45.00 ➝ $56.00Low
9/26/2018Piper Jaffray CompaniesReiterated RatingAbove Average ➝ Overweight$32.00 ➝ $56.00Medium
9/25/2018OppenheimerReiterated RatingBuy$57.00Low
9/20/2018Craig HallumInitiated CoverageBuy$52.00 ➝ $52.00Low
9/14/2018Robert W. BairdDowngradeOutperform ➝ NeutralMedium
9/5/2018OppenheimerSet Price TargetBuy$54.00High
8/30/2018Berenberg BankInitiated CoverageBuy ➝ Buy$50.00High
8/24/2018Dougherty & CoInitiated CoverageBuy ➝ Buy$45.00High
8/24/2018Bank of AmericaUpgradeUnderperform ➝ Neutral$45.00High
8/22/2018Stifel NicolausInitiated CoverageHold$25.00 ➝ $34.00High
8/20/2018Lake Street CapitalBoost Price TargetBuy$35.00 ➝ $65.00Low
8/6/2018OppenheimerSet Price TargetBuy$31.00 ➝ $38.00High
7/31/2018OppenheimerSet Price TargetBuy$31.00High
7/31/2018Lake Street CapitalBoost Price TargetBuy$35.00High
7/31/2018Piper Jaffray CompaniesBoost Price TargetOverweight$32.00High
7/31/2018Stifel NicolausReiterated RatingHold ➝ Hold$7.50 ➝ $25.00High
7/31/2018CowenReiterated RatingBuy$28.00High
7/23/2018Robert W. BairdReiterated RatingBuy$31.00High
6/22/2018Piper Jaffray CompaniesUpgradeOverweight$25.00High
6/18/2018Lake Street CapitalInitiated CoverageBuy$30.00High
5/27/2018OppenheimerSet Price TargetBuy$15.00High
5/21/2018OppenheimerSet Price TargetBuy$10.00 ➝ $15.00High
5/14/2018Piper Jaffray CompaniesUpgradeNeutral ➝ OverweightHigh
4/6/2018OppenheimerSet Price TargetBuy$8.00High
3/28/2018CowenUpgradeMarket Perform ➝ OutperformMedium
3/23/2018Robert W. BairdUpgradeNeutral ➝ OutperformHigh
3/22/2018OppenheimerReiterated RatingBuyMedium
3/2/2018Stifel NicolausReiterated RatingHold$4.00High
2/27/2018CowenReiterated RatingHoldMedium
2/27/2018CitigroupInitiated CoverageOutperform$5.50Low
2/26/2018OppenheimerInitiated CoverageBuy$5.50 ➝ $6.00High
11/19/2017Robert W. BairdReiterated RatingHold$3.00N/A
10/10/2017WedbushReiterated RatingOutperform$50.00 ➝ $17.00N/A
10/6/2017Piper Jaffray CompaniesReiterated RatingHold$15.00N/A
(Data available from 8/9/2017 forward)

News Sentiment Rating

0.99 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/10/2022
  • 5 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/9/2022
  • 6 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/11/2022
  • 5 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/10/2022
  • 6 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
5/10/2022
  • 6 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/9/2022
  • 10 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
7/9/2022
  • 11 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
8/8/2022

Current Sentiment

  • 11 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Tandem Diabetes Care logo
Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set. It also provides t:slim X2 insulin with Basal-IQ and control IQ technology; t:slim X2 with G5 Integration; and Tandem Device Updater, a tool that allows users to update their pump's software. In addition, the company offers t:connect, a web-based data management application, which provides a visual way to display diabetes therapy management data from the pump, continuous glucose monitoring, and supported blood glucose meters for users, their caregivers, and their healthcare providers; and Sugarmate, a mobile app for people with diabetes who use insulin. It has development and commercialization agreements with Dexcom, Inc. and Abbott Laboratories. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $60.10
Low: $59.65
High: $63.23

50 Day Range

MA: $60.77
Low: $53.22
High: $68.97

52 Week Range

Now: $60.10
Low: $52.08
High: $155.86

Volume

1,186,705 shs

Average Volume

892,050 shs

Market Capitalization

$3.84 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.8

Frequently Asked Questions

What sell-side analysts currently cover shares of Tandem Diabetes Care?

The following Wall Street research analysts have issued stock ratings on Tandem Diabetes Care in the last year: Bank of America Co., Citigroup Inc., Cowen Inc, Cowen Inc., Lake Street Capital, Oppenheimer Holdings Inc., Piper Sandler, Raymond James, StockNews.com, SVB Leerink LLC, TheStreet, and Wells Fargo & Company.
View the latest analyst ratings for TNDM.

What is the current price target for Tandem Diabetes Care?

10 Wall Street analysts have set twelve-month price targets for Tandem Diabetes Care in the last year. Their average twelve-month price target is $109.40, suggesting a possible upside of 82.0%. Lake Street Capital has the highest price target set, predicting TNDM will reach $150.00 in the next twelve months. Piper Sandler has the lowest price target set, forecasting a price of $80.00 for Tandem Diabetes Care in the next year.
View the latest price targets for TNDM.

What is the current consensus analyst rating for Tandem Diabetes Care?

Tandem Diabetes Care currently has 2 hold ratings and 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe TNDM will outperform the market and that investors should add to their positions of Tandem Diabetes Care.
View the latest ratings for TNDM.

What other companies compete with Tandem Diabetes Care?

Other companies that are similar to Tandem Diabetes Care include Inari Medical, ICU Medical, iRhythm Technologies, Integra LifeSciences and Haemonetics. Learn More about companies similar to Tandem Diabetes Care.

How do I contact Tandem Diabetes Care's investor relations team?

Tandem Diabetes Care's physical mailing address is 11075 ROSELLE STREET, San Diego CA, 92121. The medical device company's listed phone number is (858) 366-6900 and its investor relations email address is [email protected] The official website for Tandem Diabetes Care is www.tandemdiabetes.com. Learn More about contacing Tandem Diabetes Care investor relations.